Pravastatin, Sodium Salt (CAS 81131-70-6)
See product citations (2)
QUICK LINKS
Pravastatin Sodium Salt serves as a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway. With a high affinity (Ki approximately 1 nM), pravastatin effectively impedes the enzymatic action that catalyzes the conversion of HMG-CoA to mevalonate, a precursor to sterols, including cholesterol. This inhibition plays a role in modulating cellular processes linked to cholesterol and its derivatives. Beyond its primary action, pravastatin influences cardiovascular health through mechanisms that are still being elucidated in various research applications. Additionally, it exhibits immunomodulatory properties and affects cell signaling by inhibiting the isoprenylation of ras p21, a post-translational modification essential for the proper functioning of this protein in signal transduction pathways. These attributes make pravastatin sodium salt useful in the study of cholesterol metabolism, cardiovascular physiology, and cellular signaling.
Pravastatin, Sodium Salt (CAS 81131-70-6) References
- Statins as a newly recognized type of immunomodulator. | Kwak, B., et al. 2000. Nat Med. 6: 1399-402. PMID: 11100127
- Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. | Komai, T., et al. 1992. Eur J Drug Metab Pharmacokinet. 17: 103-13. PMID: 1425808
- Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. | Singhvi, SM., et al. 1990. Br J Clin Pharmacol. 29: 239-43. PMID: 2106337
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. | Koga, T., et al. 1990. Biochim Biophys Acta. 1045: 115-20. PMID: 2116173
- Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. | Tayel, SA., et al. 2015. Int J Pharm. 483: 77-88. PMID: 25666025
- Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. | Yoshino, G., et al. 1986. Diabetes Res Clin Pract. 2: 179-81. PMID: 3091343
- Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. | Shiomi, M., et al. 1995. Arterioscler Thromb Vasc Biol. 15: 1938-44. PMID: 7583574
- Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. | Cohen, LH., et al. 1993. Biochem Pharmacol. 45: 2203-8. PMID: 8517861
- Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. | Narisawa, T., et al. 1996. Jpn J Cancer Res. 87: 798-804. PMID: 8797885
- Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. | Kurakata, S., et al. 1996. Immunopharmacology. 34: 51-61. PMID: 8880225
- Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. | Hamelin, BA. and Turgeon, J. 1998. Trends Pharmacol Sci. 19: 26-37. PMID: 9509899
- Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. | Kaesemeyer, WH., et al. 1999. J Am Coll Cardiol. 33: 234-41. PMID: 9935036
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pravastatin, Sodium Salt, 25 mg | sc-203218 | 25 mg | $69.00 | |||
Pravastatin, Sodium Salt, 100 mg | sc-203218A | 100 mg | $162.00 | |||
Pravastatin, Sodium Salt, 1 g | sc-203218B | 1 g | $787.00 |